Holen Sie sich die Stockscreener-App
13.68
3.48%
0.46
Schlusskurs vom Vortag:
$13.22
Offen:
$13.34
24-Stunden-Volumen:
47,494
Relative Volume:
0.83
Marktkapitalisierung:
$98.64M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.5311
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
-0.58%
1M Leistung:
-13.36%
6M Leistung:
+98.26%
1J Leistung:
+28.93%
1-Tages-Spanne:
$13.26
$14.19
1-Wochen-Bereich:
$12.75
$15.12
52-Wochen-Spanne:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
13.68 | 95.32M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
What drives Atara Biotherapeutics Inc stock priceBullish Engulfing Patterns & Watch and Learn From Live Trades - earlytimes.in
Understanding the Setup: (ATRA) and Scalable Risk - news.stocktradersdaily.com
Mizuho raises Atara Biotherapeutics stock price target on reduced expenses By Investing.com - Investing.com Canada
Atara Biotherapeutics Inc Stock Analysis and ForecastEconomic Indicators Overview & Chat With Other Investors on Daily Signals - earlytimes.in
Is Atara Biotherapeutics Inc a good long term investmentCup and Handle Formations & Budget Friendly Portfolio Growth - earlytimes.in
Mizuho Raises Price Target on Atara Biotherapeutics to $18 From $16, Keeps Outperform Rating - MarketScreener
Will Atara Biotherapeutics Inc. (AT20) stock keep high P E multiplesTrade Risk Assessment & Verified Swing Trading Watchlists - newser.com
Will Atara Biotherapeutics Inc. (AT20) stock sustain uptrend momentumJuly 2025 Opening Moves & Daily Momentum Trading Reports - newser.com
Why Atara Biotherapeutics Inc. stock could see breakout soon2025 Year in Review & Expert Verified Movement Alerts - newser.com
Atara biotherapeutics CEO Nguyen sells $38437 in stock By Investing.com - Investing.com Canada
Can machine learning forecast Atara Biotherapeutics Inc. recoveryMarket Movement Recap & Low Risk Investment Opportunities - newser.com
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionJuly 2025 News Drivers & Expert Approved Momentum Trade Ideas - newser.com
Is Atara Biotherapeutics Inc. (AT20) stock attractive post correctionMarket Growth Review & Weekly Market Pulse Alerts - newser.com
How Atara Biotherapeutics Inc. (AT20) stock benefits from digital adoptionJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Can Atara Biotherapeutics Inc. stock resist market sell offsTrade Volume Report & Risk Controlled Stock Pick Alerts - newser.com
Is Atara Biotherapeutics Inc. (AT20) stock nearing a technical breakout2025 Pullback Review & Long Hold Capital Preservation Tips - newser.com
Is Atara Biotherapeutics Inc. (AT20) stock trading at attractive multiples - newser.com
How to recover losses in Atara Biotherapeutics Inc. stockQuarterly Profit Report & Reliable Trade Execution Plans - newser.com
Live market analysis of Atara Biotherapeutics Inc.Weekly Stock Report & Smart Swing Trading Techniques - newser.com
How Atara Biotherapeutics Inc. (AT20) stock performs during market turbulence2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
Custom strategy builders for tracking Atara Biotherapeutics Inc.July 2025 Drop Watch & Advanced Technical Signal Analysis - newser.com
What analysts say about Atara Biotherapeutics Inc stockVolatility Index Analysis & AI-Driven Stock Forecast Models - earlytimes.in
Will Atara Biotherapeutics Inc. (AT20) stock beat value stocksDividend Hike & Real-Time Stock Entry Alerts - newser.com
Atara Biotherapeutics Announces Third Quarter 2025 Financial Results and Operational Progress - BioSpace
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):